Clinical Trial Update: Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating dabrafenib alone or in combination with trametinib for BRAF V600E metastatic non-small cell lung cancer has completed with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Dabrafenib (Dabrafenib)
• Trametinib (trametinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-12-07